{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is BioVie, Inc. technically bullish or bearish?
As of May 1, 2025, BioVie, Inc. shows a mildly bearish trend due to daily moving averages, while mixed signals from MACD, Bollinger Bands, and other indicators suggest caution with a slight bearish bias.
Who are in the management team of BioVie, Inc.?
As of March 2022, the management team of BioVie, Inc. is led by CEO and Director Mr. Terren Peizer, with the Board of Directors including Mr. Richard Berman, Mr. Steven Gorlin, Dr. Robert Hariri, Mr. Rajah Menon, and Mr. Sigmund Rogich.
What does BioVie, Inc. do?
BioVie, Inc. is a clinical-stage pharmaceutical company focused on developing drug therapies for liver disease. As of March 2025, it has a market cap of $19.13 million and reported a net profit loss of $3 million.
How big is BioVie, Inc.?
As of Jun 18, BioVie, Inc. has a market capitalization of 19.13 million and reported net sales of 0.00 million with a net profit of -18.99 million for the latest four quarters. The company has shareholder's funds of 15.51 million and total assets of 25.21 million as of Jun'24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
